Cytokine profile determined by data-mining analysis set into clusters of non-small-cell lung cancer patients according to prognosis.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Annals of Oncology

• Publication date

  2015-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/annonc/mdu549PMID 25467015
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cancer statistics, 2014

  2014cited by this paper
• Effects of an oral nutritional supplement containing eicosapentaenoic acid on nutritional and clinical outcomes in patients with advanced non-small cell lung cancer: randomised trial.

  2014cited by this paper
• Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation fo

  2014influential reference
• Data Mining Practical Machine Learning Tools and Techniques

  2014cited by this paper
• Pegylated liposomal doxorubicin and cyclophosphamide in early recurrent ovarian carcinoma: phase I dose-finding study

  2013cited by this paper
• Inflammation and cancer-related fatigue: mechanisms, contributing factors, and treatment implications.

  2013cited by this paper
• Early detection of lung cancer risk using data mining.

  2013cited by this paper
• Circulating inflammation markers and prospective risk for lung cancer.

  2013cited by this paper
• Dose‐finding design using mixed‐effect proportional odds model for longitudinal graded toxicity data in phase I oncology clinical trials

  2013cited by this paper
• Circulating levels of immune and inflammatory markers and long versus short survival in early-stage lung cancer.

  2013cited by this paper
• ealth-related quality of life in patients with lung cancer : Validation of the exican-Spanish version and association with prognosis of the EORTC QLQ-LC 13 uestionnaire scar

  2012cited by this paper
• Association of Nutrition Parameters Including Bioelectrical Impedance and Systemic Inflammatory Response With Quality of Life and Prognosis in Patients With Advanced Non-Small-Cell Lung Cancer: A Prospective Study

  2012cited by this paper
• Proportional odds model for dose‐finding clinical trial designs with ordinal toxicity grading

  2011cited by this paper
• Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors.

  2011cited by this paper
• The pro- and anti-inflammatory properties of the cytokine interleukin-6.

  2011cited by this paper
• IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer.

  2011cited by this paper
• Antitumor activity of type III interferon alone or in combination with type I interferon against human non‐small cell lung cancer

  2011cited by this paper
• IL-28A, IL-28B, and IL-29: promising cytokines with type I interferon-like properties.

  2010cited by this paper
• Immunity, inflammation, and cancer.

  2010cited by this paper
• An approach for understanding the inflammation and cancer relationship.

  2009cited by this paper
• Cytokines as a key component of cancer-related inflammation.

  2008cited by this paper
• Cancer and inflammation: a complex relationship.

  2008cited by this paper
• Historical insights into cytokines

  2007cited by this paper
• Novel interferon-lambdas induce antiproliferative effects in neuroendocrine tumor cells.

  2006cited by this paper
• Novel interferon-λs induce antiproliferative effects in neuroendocrine tumor cells

  2006cited by this paper
• Innate immunity and angiogenesis.

  2004cited by this paper
• Tumour-educated macrophages promote tumour progression and metastasis

  2004cited by this paper
• Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group.

  2004cited by this paper
• Serum Interleukin-6 Levels Correlate with Malnutrition and Survival in Patients with Advanced Non-Small Cell Lung Cancer

  2004cited by this paper
• Cytokines and chemokines

  2003cited by this paper
• 2. Cytokines and chemokines.

  2003cited by this paper
• Inflammation and cancer

  2002cited by this paper
• Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities

  2000cited by this paper
• Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers

  1991cited by this paper
• Cancer statistics

  1989cited by this paper
• The biology of interleukin-6.

  1989cited by this paper

• Circulating cytokine profiling and clustering identify biomarker predicting efficacy of ICI in combination with chemotherapy.

  2025cites this paper
• Prognostic implication of serum levels of IL-6 and IL-10 in children and adolescents with aggressive mature B-cell non-Hodgkin lymphoma

  2025cites this paper
• Inflammatory Cytokines Associated with Obesity, Type-2 Diabetes, and Hypertension Exacerbate Breast Cancer Risk in Underserved African American and Latin American Women

  2024cites this paper
• Targeting KRAS and SHP2 signaling pathways for immunomodulation and improving treatment outcomes in solid tumors.

  2024cites this paper
• Combining Classic and Novel Neutrophil-Related Biomarkers to Identify Non-Small-Cell Lung Cancer

  2024cites this paper
• Predicting Survival in Patients with Advanced NSCLC Treated with Atezolizumab Using Pre‐ and on‐Treatment Prognostic Biomarkers

  2024cites this paper
• Clinical values of preoperative red blood cell distribution width and platelet parameters in patients with papillary thyroid carcinoma.

  2024cites this paper
• Expression of Interleukin-8, Interleukin-12 and Interleukin-13 in Esophageal Squamous Cell Carcinoma: Biomarker Potentiality and Prognostic Significance

  2024cites this paper
• Combining TIGIT blockade with IL‐15 stimulation is a promising immunotherapy strategy for lung adenocarcinoma

  2024cites this paper
• Identification of novel clusters of co-expressing cytokines in a diagnostic cytokine multiplex test

  2023cites this paper
• Prediction of individual survival and trial outcomes for anti-PDL1 treatment in non-small cell lung cancer using blood markers-based kinetics-machine learning

  2023cites this paper
• Integrated circulating tumour DNA and cytokine analysis for therapy monitoring of ALK-rearranged lung adenocarcinoma

  2023cites this paper
• Cell Type-Specific Roles of STAT3 Signaling in the Pathogenesis and Progression of K-ras Mutant Lung Adenocarcinoma

  2022cites this paper
• Multitarget and Multipathway Regulation of Zhenqi Fuzheng Granule against Non-Small Cell Lung Cancer Based On Network Pharmacology and Molecular Docking

  2022cites this paper
• Serum cytokines predict efficacy and toxicity, but are not useful for disease monitoring in lung cancer treated with PD-(L)1 inhibitors

  2022cites this paper
• Overexpression of Interleukin-8 and Interleukin-13 as potent immune markers associated with survival and dietary habits in esophageal squamous cell carcinoma

  2022cites this paper
• The Interleukin-33/ST2 Axis Enhances Lung-Resident CD14+ Monocyte Function in Patients with Non-Small Cell Lung Cancer

  2022cites this paper
• Central Roles of STAT3-Mediated Signals in Onset and Development of Cancers: Tumorigenesis and Immunosurveillance

  2022cites this paper
• Plasma secretome analyses identify IL-8 and nitrites as predictors of poor prognosis in nasopharyngeal carcinoma patients.

  2022cites this paper
• New Algorithms and Technologies for Data Mining

  2022cites this paper
• Decreased IL-6 and NK Cells in Early-Stage Lung Adenocarcinoma Presenting as Ground-Glass Opacity

  2021cites this paper
• Multicellular Effects of STAT3 in Non-small Cell Lung Cancer: Mechanistic Insights and Therapeutic Opportunities

  2021cites this paper
• A novel immunogenomic prognostic signature in lung squamous carcinoma

  2021cites this paper
• Laboratory biomarkers of an effective antitumor immune response. Clinical significance.

  2021cites this paper
• High DSCC1 Level Predicts Poor Prognosis of Lung Adenocarcinoma

  2021cites this paper
• Clinicopathological implications of lncRNAs, immunotherapy and DNA methylation in lung squamous cell carcinoma: a narrative review

  2021cites this paper
• Recombinant Newcastle disease virus expressing human IFN-λ1 (rL-hIFN-λ1) inhibits lung cancer migration through repolarizating macrophage from M2 to M1 phenotype

  2020cites this paper
• High number of CD14+B7H4+ monocytes is significantly associated with increased IL-4, IL-13, IL-10 and TGF-carcinoma

  2020cites this paper
• Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Blood to Distinguish Lung Cancer Patients from Healthy Subjects

  2020cites this paper
• Circulating Interleukin-4 Is Associated with a Systemic T Cell Response against Tumor-Associated Antigens in Treatment-Naïve Patients with Resectable Non-Small-Cell Lung Cancer

  2020cites this paper
• Understanding the Complexity of the Tumor Microenvironment in K-ras Mutant Lung Cancer: Finding an Alternative Path to Prevention and Treatment

  2020cites this paper
• Multiomic analysis of cytokines in immuno-oncology

  2020cites this paper
• Macrophage and Tumor Cell Cross-Talk Is Fundamental for Lung Tumor Progression: We Need to Talk

  2020cites this paper
• KCNQ1OT1 contributes to sorafenib resistance and programmed death-ligand-1-mediated immune escape via sponging miR-506 in hepatocellular carcinoma cells

  2020cites this paper
• KCNQ 1 OT 1 contributes to sorafenib resistance and programmed death ‐ ligand ‐ 1 ‐ mediated immune escape via sponging miR ‐ 506 in hepatocellular carcinoma cells

  2020cites this paper
• Engineered Three-Dimensional Tumor Models to Study Natural Killer Cell Suppression.

  2020cites this paper
• Abstract word count: 249 Main text word count: 2575 Title: Risk factors for lung cancer in COPD – results from the Bergen COPD Cohort Study Authors:

  2020cites this paper
• A systematic review of the overlap of fluid biomarkers in delirium and advanced cancer-related syndromes

  2019cites this paper
• Clinical Significance of Serum Type III Interferons in Patients with Gastric Cancer

  2019cites this paper
• Serum Interleukin-27 Level in Different Clinical Stages of Lung Cancer

  2019cites this paper
• Risk factors for lung cancer in COPD - results from the Bergen COPD cohort study.

  2019cites this paper
• Mast cells induce epithelial-to-mesenchymal transition and migration in non-small cell lung cancer through IL-8/Wnt/β-catenin pathway

  2019cites this paper
• Comparing efficacy and safety of regorafenib versus pemetrexed in lung cancer: A preliminary clinical trial evaluating effect of inflammatory biomarkers on disease progression.

  2019cites this paper
• Blood Predictive Biomarkers for Patients With Non-small-cell Lung Cancer Associated With Clinical Response to Nivolumab.

  2019cites this paper
• Lean Body Mass and Endocrine Status But Not Age Are Determinants of Resting Energy Expenditure in Patients with Non-Small Cell Lung Cancer

  2019cites this paper
• Comparative efficacy and safety of pemetrexed and crizotinib in Chinese patients with advanced lung cancer: A preliminary clinical trial

  2019cites this paper
• Mast cells induce epithelial-to-mesenchymal transition and migration in non-small cell lung cancer through IL-8/Wnt/β-catenin pathway

  2019cites this paper
• Investigation of IL-33 serum levels in patients with benign and malignant salivary gland tumors

  2018cites this paper
• Levels of peripheral blood polymorphonuclear myeloid-derived suppressor cells and selected cytokines are potentially prognostic of disease progression for patients with non-small cell lung cancer

  2018cites this paper
• Rab37 in lung cancer mediates exocytosis of soluble ST2 and thus skews macrophages toward tumor‐suppressing phenotype

  2018cites this paper
• IL-33 in Tumor Immunity: Nothing to Sneeze At.

  2018cites this paper
• Abstract. Our previous studies have identified that silencing oncoprotein 18 (Op18)/stathmin via RNA interference (RNAi) inhibited autocrine interleukin‐10 (IL‐10) and enhanced the sensitivity to Taxol in NCI‐H1299 non‐small cell lung cancer cells. In this study, whether autocrine IL‐10 regulates Op

  2018cites this paper
• Interplay between immune cells in lung cancer: beyond T lymphocytes.

  2018cites this paper
• Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non–Small Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab

  2018cites this paper
• Sex specific function of epithelial STAT3 signaling in pathogenesis of K-ras mutant lung cancer

  2018cites this paper
• Expression of PD-1/PD-L1 and PD-L2 in peripheral T-cells from non-small cell lung cancer patients

  2017cites this paper
• Interleukin-6 blockade attenuates lung cancer tissue construction integrated by cancer stem cells

  2017cites this paper
• Wounds that heal and wounds that don't - The role of the IL-33/ST2 pathway in tissue repair and tumorigenesis.

  2017cites this paper
• Interleukin-33 is a regulatory nuclear factor in lung cancer and wound healing

  2017cites this paper
• Depression, inflammation, and epidermal growth factor receptor (EGFR) status in metastatic non-small cell lung cancer: A pilot study.

  2017cites this paper
• Impact of IL-12 in Cancer.

  2017cites this paper
• Identification of serum inflammatory markers as classifiers of lung cancer mortality for stage I adenocarcinoma

  2017cites this paper
• Mass spectrometry-assisted gel-based proteomics in cancer biomarker discovery: approaches and application

  2017cites this paper
• IL-27 Concentration in Systemic Circulation and Tumor Micro-Circulation Samples of Sclc and Nsclc Patients; Association with Tumor Size, Histological Type and Presence of Metastases

  2016cites this paper
• A prospective study of the use of circulating markers as predictors for epidermal growth factor receptor-tyrosine kinase inhibitor treatment in pulmonary adenocarcinoma

  2016cites this paper
• Strong inflammatory response and Th1-polarization profile in children with acute lymphoblastic leukemia without apparent infection.

  2016cites this paper
• Biomarker development in the precision medicine era: lung cancer as a case study

  2016cites this paper
• The role of IL-29 in immunity and cancer

  2016cites this paper
• Non-small cell lung cancer is characterised by a distinct inflammatory signature in serum compared with chronic obstructive pulmonary disease

  2016cites this paper
• IL-33 signaling fuels outgrowth and metastasis of human lung cancer.

  2016cites this paper
• Interplay between Cellular and Molecular Inflammatory Mediators in Lung Cancer

  2016cites this paper
• Serum Cytokinome Profile Evaluation: A Tool to Define New Diagnostic and Prognostic Markers of Cancer Using Multiplexed Bead-Based Immunoassays

  2016cites this paper
• Research on Pattern Analysis and Data Classification Methodology for Data Mining and Knowledge Discovery

  2016influential citation
• IL-33 Signaling in Lung Injury.

  2016cites this paper
• IL6 Blockade Reprograms the Lung Tumor Microenvironment to Limit the Development and Progression of K-ras-Mutant Lung Cancer.

  2016cites this paper
• An antitumorigenic role for the IL-33 receptor, ST2L, in colon cancer

  2015cites this paper
• Clinical significance of serum interleukin-29, interleukin-32, and tumor necrosis factor alpha levels in patients with gastric cancer

  2015cites this paper
• Signature of cytokines and angiogenic factors (CAFs) defines a clinically distinct subgroup of gastric cancer

  2015cites this paper
• values of preoperative red blood cell distribution width and platelet parameters in patients with papillary thyroid carcinoma

  year unknowncites this paper
• Predicting survival and trial outcome 1 in non-small cell lung cancer 2 integrating tumor and blood 3 markers kinetics with machine 4 learning

  year unknowncites this paper